Birchview Capital’s Corcept Therapeutics CORT Stock Holding History

Birchview Capital’s Portfolio CORT Stock Details CORT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$4.97M	Buy	57,200 +10,000	+21%	+$604K	2.33%	10
2026 Q1	$1.9M	Sell	47,200 -20,000	-30%	-$748K	1.08%	28
2025 Q4	$2.34M	Hold	67,200	–	–	1.37%	20
2025 Q3	$5.58M	Hold	67,200	–	–	4.22%	3
2025 Q2	$4.93M	Buy	67,200 +1,200	+2%	+$87K	4.9%	3
2025 Q1	$7.54M	Sell	66,000 -8,000	-11%	-$487K	6.55%	2
2024 Q4	$3.73M	Hold	74,000	–	–	3.03%	7
2024 Q3	$3.42M	Hold	74,000	–	–	2.97%	8
2024 Q2	$2.4M	Buy	74,000 +24,000	+48%	+$657K	2.22%	13
2024 Q1	$1.26M	Hold	50,000	–	–	1.03%	22
2023 Q4	$1.62M	Hold	50,000	–	–	1.27%	19
2023 Q3	$1.36M	Hold	50,000	–	–	1.16%	15
2023 Q2	$1.11M	Hold	50,000	–	–	0.83%	20
2023 Q1	$1.08M	Hold	50,000	–	–	0.85%	19
2022 Q4	$1.02M	Hold	50,000	–	–	0.72%	21
2022 Q3	$1.28M	Hold	50,000	–	–	0.9%	21
2022 Q2	$1.19M	Hold	50,000	–	–	0.86%	21
2022 Q1	$1.13M	Hold	50,000	–	–	0.81%	20
2021 Q4	$990K	Hold	50,000	–	–	0.64%	30
2021 Q3	$984K	Hold	50,000	–	–	0.67%	29
2021 Q2	$1.1M	Hold	50,000	–	–	0.66%	28
2021 Q1	$1.19M	Hold	50,000	–	–	0.71%	24
2020 Q4	$1.31M	Hold	50,000	–	–	0.75%	22
2020 Q3	$870K	Hold	50,000	–	–	0.58%	24
2020 Q2	$841K	Hold	50,000	–	–	0.51%	29
2020 Q1	$594K	Hold	50,000	–	–	0.53%	26
2019 Q4	$605K	Hold	50,000	–	–	0.44%	30
2019 Q3	$707K	Hold	50,000	–	–	0.47%	21
2019 Q2	$558K	Hold	50,000	–	–	0.34%	30
2019 Q1	$587K	Hold	50,000	–	–	0.37%	26
2018 Q4	$668K	Hold	50,000	–	–	0.63%	19
2018 Q3	$701K	Hold	50,000	–	–	0.45%	23
2018 Q2	$786K	Sell	50,000 -25,500	-34%	-$444K	0.53%	21
2018 Q1	$1.24M	Sell	75,500 -19,500	-21%	-$361K	0.82%	12
2017 Q4	$1.72M	Hold	95,000	–	–	1.01%	9
2017 Q3	$1.83M	Hold	95,000	–	–	0.95%	6
2017 Q2	$1.12M	Buy	95,000 +35,000	+58%	+$380K	0.59%	9
2017 Q1	$658K	Sell	60,000 -20,000	-25%	-$176K	0.37%	20
2016 Q4	$581K	Hold	80,000	–	–	0.36%	17
2016 Q3	$520K	Hold	80,000	–	–	0.3%	23
2016 Q2	$437K	Hold	80,000	–	–	0.32%	24
2016 Q1	$374K	Hold	80,000	–	–	0.27%	25
2015 Q4	$398K	Buy	+80,000	New	+$361K	0.23%	25

Other funds holding CORT

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

ISL

Ingalls & Snyder LLC New York $3.66B AUM 57.76% 1-Year Est. Return

Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Parallel Advisors San Francisco, California $6.56B AUM 32.24% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Birchview Capital's CORT Position: Q2 2026 in Review

Birchview Capital increased its Corcept Therapeutics (CORT) stake by 21% in Q2 2026, buying an estimated $604K and bringing the position to 57,200 shares worth $4.97M. The position accounts for 2.33% of the portfolio, ranked #10.

Birchview Capital first reported a position in CORT in Q4 2015 and has held it in 43 quarters since. The position peaked at $7.54M in Q1 2025. 423 funds tracked by Wall St. Rank hold CORT as of Q2 2026.

Birchview Capital held 57,200 shares of Corcept Therapeutics worth $4.97M as of Q2 2026.
Birchview Capital bought 10,000 Corcept Therapeutics shares in Q2 2026, an estimated $604K.
Corcept Therapeutics made up 2.33% of Birchview Capital's portfolio in Q2 2026, its #10 holding.
Birchview Capital first reported a position in Corcept Therapeutics in Q4 2015 and has held it in 43 quarters since.
Birchview Capital's Corcept Therapeutics position peaked at $7.54M in Q1 2025.
423 funds tracked by Wall St. Rank held Corcept Therapeutics as of Q2 2026.

Based on Birchview Capital's 13F filing for Q2 2026, filed 14 Aug 2026.